Zivo Bioscience (ZIVO) Screams 2,608% Higher AFTER Reverse Split!
Okay, that's it. We are officially enamored with post reverse split trading!
First, there was our client,...
ATCC Announces $87 Million Award for Project NextGen for Vaccines, from Barda.
ATCC, the world’s premier biological materials management and standards organization, today announced a five-year, $87 million award from the Biomedical Advanced Research...
GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
(Presentation text bolding for emphasis by Editors of the Biotech Stock Review, not the company.
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at...
Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.
Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for...
Adial Pharma (ADIL). Why Quit Drinking When You Can Just Cut Back.
"ONWARD™ showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns."
Interviews With Dr. Don Diamond, Lead Developer in the GeoVax (GOVX) Vaccine for Leukemia...
Dr. Don Diamond has stated, "The City of Hope is excited to license this vaccine to GeoVax (GOVX) to progress to large-scale...
Geovax (GOVX) – City of Hope Covid Vaccine for Chronic Lymphocytic Leukemia Patients. Interview...
Explosive Interview About GeoVax's Covid vaccine with the brilliant Dr. Don J. Diamond, Ph.D., professor at City of Hope and GeoVax...
The Extraordinary Dr. Koffman, Who Beat Leukemia.
Dr. Brian Koffman is extraordinary, in many ways. He’s extraordinary in the medical sense because, after twelve years of battling blood...
GeoVax (GOVX) Conference Call at 4:30 ET, the 29th.
GeoVax to Host Conference Call at 4:30 PM ET
GeoVax to Report 2023 Financial Results and Provide Corporate...
Latest article
COVID-19 Immunity From mRNA Booster Does Not Last Very Long.
Study finds that the median length for the antibody half-life immune response was 63 days for the primary series, and increased to...
We’re in Tampa for the Kentucky Derby.
GeoVax (GOVX), Sees a Little Volume.
Normally, we get a little nervous when one of the companies we...
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
